decitabine / Generic mfg. - LARVOL DELTA

Trial in progress: Phase II Study of (early) combination salvage therapy with venetoclax and intensified decitabine in relapsed/refractory AML (VenSwitch) (ASH 2025) - P2 | "A scientific companion program includes spatial assessment of the bone marrow microenvironment under therapy and sequential transcriptomic analyses by single-cell RNA-sequencing of bone marrow samples. The trial started enrollment in November 2023 an has enrolled 18 patients to date."

IO biomarker • P2 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Lymphoma • Myelodysplastic Syndrome • FLT3 • TP53

Maintenance therapy in AML: A meta-analysis and a single center retrospective study (ASH 2025) - "Therapeutic interventions were analyzed, including CC-486, sorafenib, gilteritinib, FLT3 inhibitors, azacitidine, and decitabine. The meta-analysis suggests that maintenance therapy in AML patientsis associated with improved OS, DFS, and RFS, with particularly pronounced benefits observed in MRD+ and intermediate-risk subgroups. Although maintenance therapy increases hematologic and dermatologic toxicities, its overall safety is acceptable. The retrospective analysis indicated that the VA regimen showed certain efficacy and safety in unfit or elderly AML patients, but the study is limited in number and needs more cases and a prospective cohort study to further verify."

Retrospective data • Acute Myelogenous Leukemia • Hematological Disorders • Infectious Disease • Neutropenia • Thrombocytopenia

Meta-analysis confirms venetoclax plus decitabine as a frontline game-changer in elderly AML (Acute Myeloid Leukemia) (ASH 2025) - "This meta-analysis provides compelling evidence that VEN + DEC significantly improves remission and survival outcomes in elderly AML patients, with an acceptable safety margin. The VEN 400 mg + DEC regimen appears to offer the most pronounced clinical benefit. These findings support VEN + DEC as a front-line therapeutic option and call for further prospective trials to optimize patient selection and treatment duration"

Retrospective data • Acute Myelogenous Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Leukopenia • Neutropenia • Pneumonia • Respiratory Diseases • BCL2

Real-world characteristics, treatment modifications, and outcomes for patients with Acute Myeloid Leukemia (AML) receiving hypomethylating agents (HMA) + venetoclax (VEN) as first-line treatment (1L) (ASH 2025) - "Background: Older patients with acute myeloid leukemia (AML), those with multiple comorbidities, and/or poor performance status are generally considered ineligible for intense chemotherapy and are often treated with combination therapy of hypomethylating agents (HMAs) (azacitidine or decitabine) and venetoclax (VEN) as the standard of care. This real-world study showed that 1L combination of HMA+VEN was effective in managing AML patients that are ineligible for intense chemotherapy. However, treatment modifications due to cytopenia were common. The longer observed rwOS is likely reflective of a younger, high-functioning patient population with favorable ELN risk profile, subsequent therapies used (including stem cell transplant), and/or improvements in dose optimization in clinical practice."

Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia

Utilization patterns of venetoclax-based regimens for AML in a community based setting & representative populational analyses (ASH 2025) - "In first line setting, 22 patients (52.3%) received Venetoclax with azacitidine, 17 patients 40.1% received decitabine, 2 patients (4.8%) with cladribine and cytarabine, and 2 patients (4.8%) received Venetoclax alone...6 patients (40%) received azacitidine with venetcloax, 6 patients (40%) received decitabine, 1 patient (6.7%) received cytarabine, 1 patient (6.7%) received enasidenib, and one patient (6.7%) received nelarabine, cyclophosphamide, and cytarabine... The median age at diagnosis was 64 years (range 21-86). 47% patients were female gender. 24.5% of patients were Black or African-American, 71.4% were White, 1% were Asian, and 3.1% were more than one race."

Clinical • Acute Myelogenous Leukemia • Febrile Neutropenia • Hepatology • Liver Failure • Neutropenia • Renal Disease • CEBPA • DDX41 • NPM1 • TP53

A lean thinking approach to improve efficiency in providing immune-chemotherapy injection in out-patient service: A pivotal study (ASH 2025) - "Thus, room A can be dedicated to longer infusion times (> 2 hours, like CHOP, ABVD, obinotuzumab etc), B room for intermediate therapies (30 min-2 hours, like carfilzomib, decitabine), room D for short therapies (less than 10 minutes, like bispecific antibodies, daratumumab, bortezomib), room C for device maintenance and blood drawing, obtaining a further NVT reduction to 57 minutes but a NVTp worsening to 48%...Based on these scenarios, we developed an integrated software solution with AI functionality based on the automation of infusion station assignment, eliminating the distinction by pathology and length of treatment, reducing the average patient waiting time to 13 minutes, the in-patient stay to 23 minutes for short-term therapies, such as daratumumab and bispecifics, and 45 minutes for intermediate therapies such as isatuximab infusion. Conclusions Our approach proposes leveraging existing infrastructure resources, particularly infusion chairs, which are often..."

Clinical • Hematological Malignancies • Oncology

Post-allogenic hematopoietic stem cell transplant ( Allo-HSCT), hypomethylating-agent maintenance improves survival without increasing GVHD (Graft versus host disease) in AML/MDS( Acute myeloid leukemia/Myelodysplastic syndrome): Updated systematic review and meta-analysis (ASH 2025) - "Hypomethylating agents (HMAs) such as azacitidine and decitabine are increasingly used as post-transplant maintenance, but the magnitude of benefit after the latest clinical reports is unclear. Importantly, HMA maintenance did not increase the risk of grade III–IV acute GVHD (RR = 0.86, 95% CI: 0.38–1.94) or chronic GVHD (RR = 0.94, 95% CI: 0.65–1.34) Conclusions This updated meta-analysis demonstrates that HMA maintenance after allo-HSCT confers clinically meaningful gains in overall and relapse-free survival, driven by both reduced relapse and lower non-relapse mortality, without increasing severe acute or chronic GVHD. These data support integrating HMAs into post-transplant protocols for high-risk AML/MDS."

Retrospective data • Review • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Transplantation

Frequency of and finding risk factors for thromboembolism and major bleeding in patients with myelodysplastic syndrome undergoing allogeneic transplantation (ASH 2025) - "Four were on decitabine, 1 was on lenalidomide, and 1 was on azacitidine. Rates of TEE and bleed in MDS patients undergoing allo-SCT were similar and common at 26% and 22%, respectively. Bleeding, but not TEE, seemed to impact survival in line with one other report (Gergi et al. Blood 2024)."

Clinical • Acute Graft versus Host Disease • Cardiovascular • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Thrombosis • Transplantation

The venetoclax combined with metronomic low-dose decitabine and interferon for preventing post-transplant relapse in high-risk MDS and AML patients (ASH 2025) - "Adverse Events: Neutropenia 69% (grade ≥3: 45%); Thrombocytopenia 41% (grade ≥3: 27%); Infections 21%; GVHD 7%. Conclusion The venetoclax-based metronomic regimen significantly reduces relapse rates in high-risk MDS/AML patients post-allo-HSCT, with a manageable safety profile, supporting its utility as an optimized maintenance strategy for relapse prevention."

Clinical • Post-transplantation • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Neutropenia • Thrombocytopenia • Transplantation

Priming of bone marrow stromal cells with the epigenetic modifier decitabine overcomes stroma-mediated resistance to bortezomib in multiple myeloma cells. (ASH 2025) - "Our findings indicate that MSCs may at least partly employ an epigenetic mechanism to induce resistance to drugs in MM cells via direct interaction with latter cells. However, further investigation is ongoing to establish whether this could be a potential underlying mechanism."

Stroma • Hematological Malignancies • Multiple Myeloma

Refractory anemia with ring sideroblasts: Epidemiological survival trends and implications in a SEER population-based study (ASH 2025) - "Available chemotherapies include luspatercept, hypomethylating agents like decitabine and azacitidine in more aggressive or refractory disease, and lenalidomide in del(5q) mutation co-ocurrence. Older patients had notably higher all-cause mortality, likely due to comorbidities as well as increased risk for malignant transformation. More notably, chemotherapy, on average, was associated with worse outcomes, likely reflecting patients with more aggressive disease compared to most untreated counterparts. There is no immediately clear explanation for the modest but significant survival advantage female gender provides."

Clinical • Anemia • Hematological Malignancies • Myelodysplastic Syndrome • SF3B1

Outcomes with azacitidine versus decitabine in AML/MDS (ASH 2025) - "In AML/MDS, both azacitidine and decitabine demonstrate activity. Decitabine achieved higher overall and complete response rates but was associated with serious infections and hematologic adverse events. Azacitidine showed modest effectiveness but better tolerability."

Acute Myelogenous Leukemia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Leukopenia • Myelodysplastic Syndrome • Neutropenia • Respiratory Diseases • Septic Shock • Thrombocytopenia

Prescribing patterns in MDS/MPN syndromes (ASH 2025) - "Additionally, the prescribing patterns of Hydroxyurea, Hypomethylating Agents (HMA)- Azacitidine/Decitabine and JAK inhibitors Ruxolitinib/Cedazuridine/Pacritinib/Momelotinib/Fedratinib were analyzed in these patients. In this real-world analysis, our data demonstrate that over 90% of patients diagnosed with MDS/MPN overlap syndromes do not receive any treatment in routine clinical practice. The most prescribed medication in this cohort of patients with MDS/MPN was hydroxyurea, followed by hypomethylating medications (decitabine and azacitidine). Being untreated was associated with a significant decrement in survival, with untreated patients having up to twice the risk of death than those treated."

Atypical Chronic Myeloid Leukemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Chronic Myelomonocytic Leukemia • Hematological Disorders • Hematological Malignancies • Juvenile Myelomonocytic Leukemia • Leukemia • Myelodysplastic Syndrome • Myeloproliferative Neoplasm

Luspatercept for the treatment of myelodysplastic syndrome: A retrospective cohort study utilizing trinetx (ASH 2025) - "Secondary outcomes included overall mortality, transition to hypomethylating agent therapy (decitabine or azacitidine), and the need for allogeneic stem cell transplant...The COMMANDS trial further confirmed the superiority of luspatercept over epoetin alfa in ESA-naïve, transfusion-dependent lower-risk MDS, with a higher rate of RBC-TI ≥12 weeks and a concurrent mean hemoglobin increase ≥1.5 g/dL during weeks 1–24 (60% vs. 35%, p<0.0001)...Conclusion Our findings suggest that luspatercept can provide meaningful and durable benefits for a substantial subset of patients and may serve as an important component of therapy in appropriately selected individuals with very low to intermediate-risk MDS. Future studies are necessary to evaluate which patients would most benefit from treatment with luspatercept."

Retrospective data • Aplastic Anemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • SF3B1 • TGFB1

Rapid transformation from JAK2-positive PMF to acute leukemia: Therapeutic challenges and rare DIC in an aggressive disease course (ASH 2025) - "Emergency leukapheresis and hydroxyurea were started for cytoreduction...Treatment options considered included combination chemotherapy with low-dose cytarabine (Ara-C), cladribine, and venetoclax, versus a palliative approach due to the patient's declining functional status and aggressive disease biology... This case underscores the clinical significance and poor prognosis associated with leukemic transformation of JAK2-positive PMF, particularly in the presence of high-risk mutations such as RUNX1 and TP53. These mutations not only predict an aggressive clinical course but also portend resistance to conventional hypomethylating agents. While decitabine provided initial stabilization, the early relapse highlights the limitations of current therapies in such molecularly adverse settings."

Acute Myelogenous Leukemia • Back Pain • Fibrosis • Hematological Malignancies • Immunology • Leukemia • Metabolic Disorders • Musculoskeletal Pain • Myelofibrosis • Myeloproliferative Neoplasm • Nephrology • Renal Disease • Thrombocytopenia • ABL1 • BCR • JAK2 • RUNX1 • TP53

Decitabine enhances the cytotoxic effect of ruxolitinib in myeloproliferative neoplasms by targeting SR splicing factors (ASH 2025) - "In current study, we demonstrated that the combination of decitabine and ruxolitinib synergistically inhibited cell viability and promoted apoptosis of SET-2 both in vitro and in vivo . Then, we explored the molecular mechanisms behind the synergistic effect, and found SRSF1 and SRSF2 both declined in the combination treatment. These findings provide valuable insights for the development of novel therapeutic strategies for MPNs."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • ABL1 • BCR • CASP3 • SRSF2

Predictive significance of early bone marrow MRD response assessment in Acute Myeloid Leukemia patients treated with venetoclax plus decitabine induction therapy: Real-world data from India (ASH 2025) - "However, a significant proportion of newly diagnosed AML patients are often ineligible for 3+7 induction therapy and are being treated with venetoclax (VEN) plus hypomethylating (decitabine/azacitidine) therapy...Patients who achieved CR after two cycles received either high-dose cytarabine consolidation or continuous VEN+decitabine therapy...CONCLUSION In our single-centre experience, venetoclax plus decitabine induction therapy using generic preparations of venetoclax was observed to be highly effective & relatively safe in newly diagnosed AML patients who were considered ineligible for intensive induction regimens. VEN+decitabine therapy was associated with significant myelosuppression & delayed haematological recovery, but this could be effectively managed with intensive supportive treatment."

Clinical • Real-world • Real-world evidence • Acute Kidney Injury • Acute Myelogenous Leukemia • Febrile Neutropenia • Infectious Disease • Nephrology • Neutropenia • Pneumonia • Renal Disease • Respiratory Diseases • Septic Shock • Thrombocytopenia • DNMT3A • NPM1 • RUNX1 • RUNX1T1

IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent (ASH 2025) - "All pts received at least one cycle of HMA therapy, consisting of either azacitidine (75 mg/m²) or decitabine (20 mg/m²), combined with venetoclax, typically dosed at 100mg daily with posaconazole prophylaxis. The primary limitations of this study include its retrospective design, sample size, and variability in the timing of response assessment. Despite these limitations, this study supports further development of treatment-specific, genetics-enhanced, and response-based prognostic tools in AML."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • FLT3 • IDH1 • IDH2 • NPM1 • TP53

Re-treatment of relapse in elderly AML with time-limited venetoclax-based regimen: A case report and literature review. (ASH 2025) - "He received eight cycles of low-dose cytarabine (LDAC; 20 mg/m 2 ) with VEN 100 mg daily added after the first five cycles...Fourteen patients were initially treated with decitabine, and one with azacitidine.(Othman et al.,2020) We hypothesise that the time-limited initial treatment may have reduced the risk of resistance and enabled disease sensitivity in re-treatment...Further data from prospective studies assessing the efficacy and safety of VEN re-treatment and establishing the role of molecular monitoring are required. The role of time-limited VEN therapy as a method of preventing treatment resistance and limiting treatment-related toxicity remains an important question in the transplant-ineligible cohort, given the poor prognosis and limited options of R/R AML post-VEN and HMA therapy."

Case report • Clinical • Review • Acute Myelogenous Leukemia • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Neutropenia • FLT3 • IDH2 • NPM1 • SRSF2 • TET2

Efficacy of a 14-day venetoclax regimen in combination with a hypomethylating agent for Acute Myeloid Leukemia: A single-center retrospective analysis (ASH 2025) - "In our study, we examine the safety and outcomes of a 14-day regimen of venetoclax in combination with azacitidine or decitabine for treatment of AML at our institution. A shortened 14-day course of venetoclax induction therapy provided comparable rates of overall response, complications, and 4-week mortality as those who received the full 28-day regimen in the pivotal VIALE-A trial. Differing from previous literature, our cohort also included patients with relapsed/refractory AML. Our study is unique in including a more diverse patient population with increased comorbidities; unlike the VIALE-A trial, our study included a greater than 40% minority population and a significant number of ECOG Grade 3 and 4 patients."

Combination therapy • Retrospective data • Acute Myelogenous Leukemia • Febrile Neutropenia • Hematological Malignancies • Infectious Disease • Leukemia • Pneumonia • Respiratory Diseases • ASXL1 • FLT3 • RUNX1 • TP53

Time burden of treatment with parenteral hypomethylating agents in combination with venetoclax among patients with newly diagnosed Acute Myeloid Leukemia (ASH 2025) - "INTRODUCTION: Standard of care for patients with newly diagnosed acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy is a parenteral hypomethylating agent (HMA) - azacitidine or decitabine, also referred to as DNA methyltransferase inhibitors - combined with oral venetoclax. Patients with newly diagnosed AML ineligible for intensive chemotherapy spend over a third of their time engaged in medical care, and a substantial portion of this time is dedicated to receiving HMA therapy. These findings highlight a substantial time burden among patients and a need for alternative effective treatment options to optimize the delivery of medical care."

Clinical • Combination therapy • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome

Prospective clinical study on the efficacy and safety of the DCIA±X regimen in treating relapsed/refractory acute myeloid leukemia (ASH 2025) - "The DCIA±X regimen—combining decitabine, cladribine, idarubicin, cytarabine, and optional targeted agents (X)—leverages synergistic mechanisms to overcome chemoresistance. This novel reinduction regimen demonstrated robust activity and acceptable toxicity in treating R/R AML patients, achieving high CR/CRi and ORR rates, facilitating successful bridge to transplant in most responders, and promising 1-year RFS and OS."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia

Venetoclax plus hypomethylating agent as first- and second-line treatment in patients with AML: A single-center experience (ASH 2025) - "The majority received azacitidine plus venetoclax; only 3 patients were treated with decitabine plus venetoclax. Our data show poorer outcomes compared to the VIALE-A trial, even among patients treated in the first-line setting. However, outcomes for patients treated in the relapsed/refractory (r/r) setting were not inferior. Notably, our cohort included a significant proportion of patients with myelodysplasia-related AML and secondary AML arising from prior myeloproliferative neoplasms."

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Myeloproliferative Neoplasm

Chidamide-based epigenetic therapy for relapsed/refractory Acute Myeloid Leukemia (ASH 2025) - P2 | "A total of 13 Asian Chinese subjects were enrolled in this study, including 9 males (69.2%) and 4 females (30.8%). The age range was 19 to 85 years old, with the youngest being 19 years old and the oldest being 85 years old, and the median age was 49 years old. 8 patients received chidamide combined with a hypomethylating agent (decitabine or azacitidine) plus daunorubicin and cytarabine or the HA regimen; the other 5 received chidamide combined with a hypomethylating agent (decitabine or azacitidine) and venetoclax."

Acute Myelogenous Leukemia • Gene Therapies • Hematological Malignancies • Leukemia

Venetoclax with hypomethylating agents versus intensive chemotherapy as induction therapy in patients with newly diagnosed acute monocytic leukemia (ASH 2025) - "Patients received either IC with the 7+3 regimen (IA group) or VEN+HMA (VEN group: venetoclax + azacitidine or decitabine). These findings suggest suboptimal long-term efficacy of VEN-based induction in this subtype, potentially due to intrinsic venetoclax resistance linked to monocytic differentiation(8). Further studies are warranted to optimize induction strategies for AML-M5."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia